Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 2/20 | 0.57 |
| ▸ | STIM1 | Q13586 | 3/20 | 0.47 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17766353 | 0.83 | STIM1 (0.43) | IL2STIM1ORAI1MAPK11MAPK14 | |
| SCHEMBL17766374 | 0.83 | STIM1 (0.50) | IL2STIM1ORAI1MAPK11MAPK14 | |
| SCHEMBL16362066 | 0.79 | STIM1 (0.58) | IL2STIM1ORAI1S1PR2S1PR4 | |
| SCHEMBL17766401 | 0.76 | STIM1 (0.59) | IL2STIM1ORAI1S1PR2S1PR4 | |
| SCHEMBL8261510 | 0.73 | IL2 (0.79) | IL2STIM1ORAI1MAPK11MAPK14 | |
| SCHEMBL5273629 | 0.73 | IL2 (1.00) | IL2MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL15942551 | 0.73 | IL2 (0.83) | IL2STIM1ORAI1MAPK11MAPK14 | |
| SCHEMBL8261504 | 0.73 | IL2 (0.68) | IL2STIM1ORAI1MAPK11MAPK14 | |
| SCHEMBL15528193 | 0.71 | IL2 (0.47) | IL2STIM1ORAI1MAPK11MAPK14 | |
| SCHEMBL5274000 | 0.70 | IL2 (0.83) | IL2STIM1ORAI1MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | claimed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | claimed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | RYR2, NR2C2, CACNA1E | IL2 2831/4885STIM1 303/4885ORAI1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.